SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " hiv " 628 found 🔀 AI-powered Shuffle
Action! NSF–DOE Vera C. Rubin Observatory Begins Capturing the Greatest Cosmic Movie Ever Made
The wait is over: NSF–DOE Rubin Observatory, funded by the U.S. National Science Foundation and the U.S. Department of Energy’s Office of Science, is now capturing the cosmos in unprecedented detail, transforming the way we study the dynamic Universe.
‘AIDS is not over:’ Behind a local group’s awareness campaign for HIV funding
Walk through East Liberty, Bloomfield or other Pittsburgh neighborhoods and you might see flyers with black-and-pink block print and an urgent message:...
Design and Early Implementation Outcomes of a Mobile Health-Enabled Social Support Intervention for Adults Living With HIV and Type 2 Diabetes in Uganda
Background: Adults living with HIV and type 2 diabetes experience complex treatment demands that affect medication-taking, clinic attendance, privacy, social support, and engagement with care. M...
Shelby County Health Dept. offers free HIV testing
In honor of National HIV Testing Day, the Shelby County Health Department hosted free testing on Saturday, and they urged anyone thinking about getting tested to do it now.
How Brad Pitt appears in “Jackass: Best and Last”: 'It was wild,' says Steve-O
The "Inglourious Basterds" actor shows up in the latest "Jackass" movie via archival footage from 2001.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Monthly BAT Days Initiative Connects Residents to Free Health, Recovery and Support Services
On the second Wednesday of each month, these organizations come together at the Centers for Addiction and Mental Health Programs (CAMP) on Orange Blossom Trail to provide HIV and Hepatitis-C testing, connections to affordable or free primary care providers, mental health resources and case management services.
The Siege of Death Mire begins: Submit your results
Help to decide the fate of a key Armageddon hive.
World’s 1st HIV-to-HIV lung transplant performed at NYU Langone Health
The surgery brings new hope for HIV-positive patients in need of lung transplants, as it opens a pool of potential donors who were previously ineligible.
Public invited to trivia with scientists gathering from around the world in Lead
Dakota Shivers Brewing in Lead will host a series of pub talks and trivia nights featuring physicists from the workshop posing science-related questions.
Dinosaurs invaded downtown St. Paul for blockbuster 1986 Science Museum exhibit
The brontosaurus and a 10-foot-tall Tyrannosaurus rex had been floated down the Mississippi River from Minneapolis that morning on coal barges to drum up publicity for the exhibit. It worked.
Philadelphia-area STI disparities still fueled by stigma and misinformation, health care leaders say
At a Philadelphia panel on HIV and health equity, experts pointed to gaps in education, funding and access to care.
WCC publishes “HIV and Mental Health: What Can the Church Do?”
The World Council of Churches (WCC) has published “HIV and Mental Health: What Can the Church Do?” by Dr Sue Parry, a practical and theologically grounded resource for congregations ready to respond to one of the most complex pastoral challenges of our time.
Sony drops “PC”, adds “AI” to official PlayStation business strategy summary
Sony had made some conspicuous edits and updates to its description of PlayStation’s “business environment and strategy,” in a new annual report filed to the U.S. Securities and Exchange Commission today. These changes are part of a 379-word overview of Sony’s strategy for its Game & Network Services (G&NS) division, which is another name for PlayStation. The chunk about PlayStation strategy is part of a voluminous financial report filed by Sony each June. This year’s is 229 pages long. Differences to any part of the filing—word changes made from year to year, as Sony provides a breakdown of its business for investors—can be illuminating. For example: A line from 2025 about how the PlayStation team “aims to achieve sustainable and profitable business growth” has been changed in the 2026 version to “aims to achieve sustainable business growth.” Notice which word they cut? That’s a pretty clear tell about how Sony expects its profit margins to be squeezed this year, due to rising chip costs for its hardware, among other things. A line from 2025 that stated “Sony plans to continue its efforts to deploy its first-party titles to multiple platforms such as PC” had been cut from the 2026 version. That appears to be Sony’s admission by omission that it has backed off releasing its biggest games on PC. Bloomberg’s Jason Schreier reported in March and again in May that Sony’s big single-player marquee games are no longer planned for time-delayed release on PC.1 A whole new chunk has also been added about how “Sony is utilizing AI to unleash the creativity of studios and further enhance the PlayStation experience.” A full breakdown of the changes made from the 2025 version to the 2026 version is below. I’ve redlined them for you…
UToledo Health offering free HIV, syphilis testing
The testing will be held on June 24 at the Walgreens at 4580 Monroe St. in Toledo from 11 a.m. to 5 p.m.
Why Is Sexual Health Still Overlooked in Chronic Pain Care?
Experts urge clinicians to address intimacy and sexual well-being routinely, noting that chronic pain often affects relationships, self-esteem, and quality of life.
Is Abridge’s ‘patient centered’ claim a bridge too far?
In this edition of AI Prognosis, Brittany Trang takes a close look at ambient scribe developer Abridge's claim about being patient-centered.
Sally Field couldn’t understand this classic Hollywood actor on set: 'I don’t know if he was stoned or what'
Sally Field is revealing the classic Hollywood actor who she just couldn't understand at all whenever they interacted on set.
Main Library exhibition honors legacy businesses
The San Francisco Public Library is this summer exhibiting archival items from businesses that have operated in The City for at least 30 years.
Can you answer these 35 'Jeopardy!' clues about rock music?
Stacker compiled a list of clues about rock music using J! Archive.
Can you answer these 35 'Jeopardy!' clues about rock music?
Stacker compiled a list of clues about rock music using J! Archive.
From the archives: Here's where Wilmington partied in the 1980s
Wilmington had a wide range of entertainment options in the 1980s.
Global HIV prevention declined drastically after Trump aid cuts, U.N. finds
Cuts from the U.S. and others have hit hard, with the number of people receiving PrEP dropping by 38% from 2024 to 2025, according to data from 62 countries.
Missed out on securing Charli XCX presale tickets? Here’s how to score last-minute ticket deals fast
Set to take place over the course of September and October, the limited run takes the pop icon to several major markets throughout the U.S.
RPG Maker forum users are racing to archive almost 15 years of valuable resources, as game engine maker announces impending move
With a transition to a new forum planned, years of posts, private messages, and accounts will all be wiped this December.
Trump Started a Plan to Eradicate HIV. He Never Finished It.
The president’s first-term pledge to end HIV in the U.S. by 2030 has evaporated in his second term.
RPG Maker is deleting 14 years of community content and fans have days to save them
RPG Maker’s official forums are closing in December, and 14 years of tutorials and guides will be permanently deleted with no archive or backup.
Vote in our L.A. Sports Hall of Fame (NHL edition)
Introducing the L.A. Times Sports Report Hall of Fame, where readers vote for Hall of Famers in various categories.
In a Divided America, the Road from Obama to Trump | FRONTLINE | PBS | Official Site
Newly available on YouTube, part two of FRONTLINE’s archival documentary series ‘Divided States of America’ traces the rise of the polarization and division that continue to define U.S. politics today.
New Joy-Con Colours And A Stand-Alone Direct Are Inbound For Splatoon Raiders
Shiver down your spine
Highly effective prevention drug arrives in South Africa, which has world’s highest HIV burden
South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention that the president calls a turning point in a country with the world’s highest burden of HIV.
We can create the future of science right now
Paul Litvak is the founder and Executive Director of the Robyn Dawes Institute and a Visiting Scholar at UC Berkeley. He has a PhD in Behavioral Decision Research from Carnegie Mellon where he studied emotions and the sunk cost bias. Over 15 years in industry, he solved a wide range of challenging technical problems. At Meta he created models optimizing the ad review process. At Google he ran experiments to measure social influence. At Airbnb, he was a product manager leading machine learning teams optimizing search ranking and price suggestions. He also co-founded and led product at Rhythmic Health, a venture-backed biosensing startup, creating an accurate low cost system using a color changing strip and a smart phone to measure salivary lactate. The bottleneck At this point, it is uncontroversial to say that science needs to stop using the PDF article as the unit of knowledge and currency. The unbearable slowness of scientific publishing, the profit motive and margins: I’m not saying anything new. The PDF also sucks because it’s hard to extract structured information, which makes it hard to do evidence synthesis. As a result, we do much less evidence synthesis than is needed. And evidence synthesis ultimately undergirds most policy and medical decision-making. I can see second-by-second real-time odds for any sporting or newsworthy event, but a school board can’t see the best evidence on whether their 8th graders should be taught algebra. As a society, we don’t treat this as an important problem. Again, not controversial. Not only is the problem well understood, but the solution has already been laid out. What we need is AI-assisted living evidence synthesis - (1) an open knowledge graph of atomic claims, (2) claims linked to evidence, (3) assessment and synthesis of each piece of evidence, and (4) continuous updating with new data. What few realize (yet) is that the technical capacity to build this vision for a significant portion of science already exists. Not only that, scientists and startup teams are already building many of these components. I know this because I’ve been surveying the space and talking to many of the builders. There are some missing pieces: for example, evaluations of how well some of the components work. But at this point, most of what’s missing is a fully end-to-end working integration of all of these parts. In the rest of this essay, I’m going to lay out all the parts of a working living evidence layer for science and who is working on them, and propose concrete next steps for building this system. What’s now possible The diagram above outlines the components of a living evidence synthesis platform, including some of the teams working on each component1. Scientific PDFs are processed into claims with associated evidence. The evidence is subjected to a forensic audit, methodological evaluation and robustness and reproducibility checks. Finally it’s given a weight in a continuously updating synthesis. What follows is a description and status of each component and a few of the teams working on them. Document understanding The first thing you need to be able to do is turn an article into structured data. Mostly that means parsing PDFs. There are often multicolumn layouts that confuse non-specialized PDF to text processing libraries. For scientific papers, there is the added complexity of parsing formulas and tables and figures. This is a really hot area - there are startups offering APIs, and it seems like a new open source package gets posted to Github every few weeks. What follows isn’t exhaustive. A package called GROBID was the state of the art for a while, they didn’t update their package for nearly two years until very recently. In the meantime reducto.ai released an AI powered PDF extraction API, PaddleOCR became popular, IBM released a model called Docling, and both Mistral and Gemini created models and libraries. I also know of at least one other well-funded psychology research group working on a paper parser. By contrast, there are few open evals in this space, with no extensive evals for complex table comprehension in particular. Nonetheless, I’m confident this will be a solved problem soon, given the combination of LLM advances and developer interest. Hypothesis level extraction There has been increasing interest in comprehending the extracted text of papers and linking information to evidence for each hypothesis. A lot of work has already been done. Trialstreamer (Marshall et al. 2020) and RobotReviewer LIVE (Marshall et al. 2023) demonstrated automated extraction of trial population, intervention, and outcome at scale on clinical RCTs. PaperQA2 (Skarlinski et al. 2024) and Ai2 ScholarQA (2024) extended this to retrieval-augmented question answering with citation grounding. Elicit, Consensus, and SciSpace operationalized claim-level extraction for end users. OpenEval (Booeshaghi et al. 2026) is the most recent and most ambitious: 1.96 million atomic claims extracted from 16,087 eLife manuscripts using Claude Sonnet 4.5, grouped into ~299,000 results, with LLM evaluations showing 81% agreement with human peer review on a 2,487-paper subset. None of these solutions link claims to test-statistics, as you would need to evaluate randomized controlled trials. This is why I built the evidence.guide API - to extract hypotheses and associated test statistics from behavioral science papers. The best public eval of this kind of extraction I’m aware of comes from the recent SCORE project - they had humans code thousands of psychology papers to extract their claims by hand. It would be extremely helpful to the world if all scientific PDFs were available as structured open data. I’ve been working to make this happen, both directly at Berkeley and through coordination with large entities I can’t yet speak of; as hard as it is to do, I think it’s possible2. Forensic audit A lot of work has been done on forensic audit, but some gaps remain. Of course, for biology papers that rely on images for evidence, there are a variety of tools (notably Proofig and ImageTwin) to spot anomalies. These are still well short of what sleuths like Elizabeth Bik can do on her own, but these tools are constant companions among fraud analysts. There’s someone working on auditing Excel files for anomalies, and a number of teams are automating numerical checks like GRIM and SPRITE, including Scrutiny project, the INSPECT-SR team as well as statcheck. The regcheck team is building a way to use AI to compare preregistrations to analyses in papers, to ensure there aren’t significant deviations. Nonetheless, there are many other kinds of anomalies to screen for, both public and less publicly known. And there are no formal evals for anomaly detection that I’m aware of. Still, there’s a lot to draw from in this space and I’m pretty certain we will be able to scan papers for most kinds of obvious anomalies in the near future. Methodological review This area has been white hot, though I fear for many of the startups in this space, because this capability may become commoditized. There are at least six different AI peer review companies, including Refine.ink, Reviewer3, ReviewerZero.ai, Q.E.D. Science, Paper Wizard, and Isitcredible. Coarse (a pun on refine) was also recently created as an open source alternative. These systems provide qualitative feedback on the content of papers, spotting methodological weaknesses and mathematical errors. They seem to work pretty well, and many academics report bitterly that they exceed the average quality of typical peer reviewers. But there are few evals here either. What evals exist so far involve using LLM-as-judge (circularity problems abound) or comparing against human reviews of questionable quality. What you’d ideally want is an eval that measures capturing known errors in papers3. Reproducibility and robustness Another active area has been using AI agents to automate computational reproducibility4 and robustness5 checks in papers that report numerical results. For more recent papers where data and code are available, AI agents can see whether they can re-run the analyses and produce the numbers reported in the published paper. In addition to a handful of individual academics who have been experimenting using Claude Code for this, the Institute for Replication is a leading group working on building an end to end system. The evals related to this problem are the most mature, with CORE-Bench (Siegel, Kapoor, Narayanan 2024) and PaperBench (OpenAI 2025) available to benchmark agents on this task. There is also work on getting AI agents to test alternative ways of analyzing the data to ensure the results are robust to small analytic design choices. Synthesis This is the most underdeveloped area where significant investment is required. Although some automated evidence synthesis systems exist — for example, otto-sr is building an AI agent to write systematic reviews — none of these incorporate the full range of paper level signals to weight evidence appropriately. Nor is there anything like an eval or a gold standard for a good systematic review. Arguably Cochrane reviews are the closest we have to gold standard human systematic reviews, though I’ve heard academics in the know complain about their uneven quality. A key question for a synthesis platform is how to weight anomalies and methodological issues in assessing the quality of a piece of evidence. This is an unsolved problem and one I’m very keen to work on. Continuous updating There are many pieces of basic infrastructure available for monitoring for new research and initiating updates. OpenAlex is the current open citation graph. Retraction Watch integrated into Crossref in October 2023. Scite tracks how citations support, contrast, or mention prior claims. The Living Evidence Network demonstrated continuous-update workflows in clinical guidelines. Engineering this is a relatively straightforward task. When you look over this technical architecture and all the progress being made, it’s hard not to be optimistic that a living guide to scientific evidence will be built. The stakeholders are ready The social infrastructure for this is starting to coalesce — it’s not just a pie in the sky academic exercise to imagine this coming into existence. Institutions like the Center for Open Science, the Institute for Replication, the INSPECT-SR, the Living Evidence Network and more are all working on scaling work to improve research quality. Funders are also aligned. The Sloan Foundation has funded living evidence work through COS. Coefficient Giving supports the Institute for Replication and COS. The Astera Institute and the Institute for Progress have shown interest in this space. NIH has established an Office for Replication and Reproducibility. Although there are (very unfortunately) serious headwinds in science funding generally, there is an active group of funders interested in metascience. A brief word about what I’ve been doing at RDI. First, as a Visiting Scholar at Berkeley I’ve been actively figuring out how a non-profit and a public university can conduct and make public the results of large-scale academic article data mining. With some of the money I raised from donors, I commissioned a legal analysis of recent case law and publisher text data mining (TDM) agreements in order to understand whether a massive open data mining of academic articles is possible (with caveats, it is). I’ve also been working to bring together stakeholders in this space, and identify gaps. I’ve also been doing some software development in this space, with more to come. A pilot proposal The assumption undergirding all of this is that an AI, given all this information, would make the right judgment about a scientific claim with lots of conflicting evidence, weighing all the factors appropriately. That’s the hypothesis we need to test. Randomized control trial research is the best place to focus on first. RCTs are used to make many of the important decisions in society - from medical trials to public policy changes. And they use a relatively uniform set of inferential statistics with lots of known and available diagnostics. Behavioral science experiments, within the broader realm of RCTs, should be first used as a testbed whose results can be generalized. Because behavioral science is at the vanguard of open science practices, replications abound (there are thousands of them) to serve as ground truth training data. Key Hypothesis Therefore the pilot would test, in behavioral RCTs that have been replicated, whether the quality of evidence for a claim can be used to accurately predict whether that claim will replicate. Secondary Hypotheses Compared to claims that replicated, non-replicated claims demonstrate a greater share of forensic anomalies in their source literatures. Hypothesis level claim and statistic extraction is accurate enough to scale living evidence without onerous human review costs. Replication prediction is more accurate than prediction markets6 or journal prestige. If all the different quality signals we gather do accurately predict which studies will replicate, then we can use that model to score evidence to power the living evidence layer. Why this is informative regardless of outcome If the pilot succeeds, the architecture extends to medical RCTs (where Living Evidence already operates and integration is mostly about claim representation), then to slices of basic biology with stable replication structure. If it fails, the field learns which quality signals are load-bearing and which ones metascience has oversold. Either result is a contribution to knowing what the literature supports. Implications for funders Because this burgeoning ecosystem of builders already exists, a well-informed philanthropic or government funder could play a crucial catalyzing role in bringing this future about. They could play at least three roles: creating open structured datasets, publishing open benchmarks and incentivizing the solving of key technical challenges. First, open archives of papers that the government maintains, like PubMed, could be turned into structured data amenable to large scale metascience and claim aggregation. I know the US government already has an interest in doing this, though some key open questions remain unanswered. How do you determine the best models and systems for accurately extracting information from papers? How can you establish a robust way to allow researchers to flag errors and correct them? And finally, how do you create a legal regime in working with publishers to maximize the scope of available papers? For the latter, a university or a private philanthropy may be better positioned to make structured data publicly available under journal subscription terms or fair use. Philanthropists or government funders could also coordinate to create or commission benchmarks that evaluate whether important problems have been solved. For example, an open benchmark for claim extraction from a range of different scientific article types would be extremely helpful. Ensuring the underlying data are accurate is vital for creating these evaluations. I’ve discussed opportunistically using various human-created datasets for this purpose, but a consistent problem is that errors in human data make it difficult for them to serve as a gold standard. Finally, with structured data and benchmarks available, the government or private philanthropy could use them to incentivize groups to develop machine learning systems that meet these benchmarks. Prizes are one potentially valuable tool for this. For example, you could establish a prize for a system that accurately updates a living meta-analysis for a small set of claims. Prizes are particularly useful as signals of problem importance, and can help create vibrant ecosystems of public and private research—see, for example the role the government played in kickstarting the current work on nuclear fusion. Conclusion The drawbacks of the current scientific publishing system are known. Scientists agree, metascientists agree, philanthropists agree: the published PDF plus citation graph isn’t the right substrate for maintaining a representation of the evidence base in science. The pieces needed to build the alternative either already exist or are rapidly taking shape. The community is forming around exactly this problem, with concrete partnerships and shared infrastructure. A pilot should start on behavioral science RCTs because that’s the slice of empirical science most amenable to legibility, where replication ground truth is richest, and where the failure modes are best documented. What’s been missing is the galvanizing mission to assemble these pieces into something that works. That’s what I’m proposing to build. *** 1 I have a broader field map that I’ll release publicly soon. This is me, building in public! 2 If this is something that you are excited about, please reach out and talk to me. 3 More on this very soon too! 4 This tests whether, given the code and the data, you can get the same statistics as reported in the published paper. 5 This tests whether the results are the same as a paper’s given alternative analytical decisions in conducting the analysis (like outlier omission). Closely related is the idea of a “multiverse” where you come up with many different ways of answering the same underlying research question with the same data, and test whether the results hold in all those alternative methods. There’s been work on the latter as well. 6 Some of the replications, e.g. those from the SCORE project, had paired the experiments with forecasts from prediction markets. So we get to look at this for free.
Sacramento County residents can track local health trends in real time. Here’s how
County officials said the new portal will make public health information easier to access and explore.
Data centers and surveillance pricing big issues for N.Y. Legislature
Friday was the last day of session.
This NYC LGBTQ+ Health Clinic Is Giving Away the Ultimate Pride Month Survival Kit
Callen-Lorde is offering LGBTQ+ New Yorkers free kits packed with HIV prevention medication, sexual health supplies, and overdose reversal drugs throughout June.
This NYC LGBTQ+ health clinic is giving away the ultimate Pride Month survival kit
Callen-Lorde is offering LGBTQ+ New Yorkers free kits packed with HIV prevention medication, sexual health supplies, and overdose reversal drugs throughout June.
Vanderbilt Health Pets of the Day: Freddy and Cooper
Today’s first Dog of the Day is Freddy, submitted by Beth Piazza of the Vanderbilt-Ingram Cancer Center. “Freddy was adopted on Valentine’s Day of 2024 from the Nashville Humane Association. He is the cuddliest 90-pound lap dog.“ Today’s second Dog of the Day is Cooper, submitted by Brandie Taylor of Medicine. “Cooper is a 14 year old chocolate lab. He loves eating and going to get pup cups!” Freddy and Cooper were featured in the June 9, 2026, edition of MyVUMC News. To see the archived collection of Vanderbilt Health Pets of the Day, go to: https://news.vumc.org/section/voice/pets-vumc/. Pet photos wanted! The Vanderbilt Health Pets of the Day are posted to the Voice section of Vanderbilt Health News and included in regular editions of the MyVUMC News newsletter, which is published twice a week by Vanderbilt Health News and Communications. Now through July 6, we especially want to see photos of your pets enjoying spring and summer. That might be having fun at the lake or beach, hanging out in the backyard, lying on the couch, or in the case of a pet fish, just living the life aquatic (we’re not too strict about what constitutes enjoying spring and summer). If you have a pet picture you would like to send in for consideration, go to the submission form here and follow the guidelines.
The Frustrating Fight to Control AIDS
When I first approached the administration of the Fenway Community Health Center in June, 1980 to set up a research program, I was surprised that I was rebu ...
Scientists uncover a new hiding spot for HIV
An Ebola update, Trump to strip job protections of NIH officials, and more health news from Morning Rounds
Deep South HIV prevention care has gaps where patients need it most
A recent University of Mississippi study has identified hundreds of counties in the South where HIV prevention and health care may not be keeping pace with the local needs, leaving communities without ...
People with cancer or HIV could lose Medicaid under new work rules, advocates say
Adults on Medicaid will be required to work 80 hours per month. The Trump administration says people who are sick will have to prove they are too sick to work to be exempt from the new work rules.
Flashback: How the Obama Era Revealed Deep Political Divisions in America
Now available on YouTube, part one of FRONTLINE’s archival series ‘Divided States of America’ traces the rise of the partisanship and gridlock that continue to define U.S. politics today.
APLA Health food pantries a lifeline for people living with HIV in Los Angeles
One grocery bag at a time, APLA Health's Vance North Necessities of Life Program in North Hollywood is helping empower people and provide hope.
Community unites for Fenway Health’s Strides for Action 5K in Boston
Hundreds of advocates and community leaders came together Sunday morning to support HIV prevention and treatment, LGBTQIA+ health services, research, and advocacy.
HIV, Brain Health Research, and How It Could Benefit Everyone
Brain health research in people living with HIV could improve existing treatments and facilitate discovery of new interventions for other diseases.
How a health clinic in South Africa is navigating Trump's cuts to HIV funding
Community health programs in South Africa have been heavily impacted by U.S. cuts to global aid. Which means there are fewer community and health workers to support low-income people with HIV and AIDS.We recently visited one of those programs, called We Care, to learn more about the experiences of the few employees who still remain.For sponsor-free episodes of Consider This, sign up for Consider This+ via Apple Podcasts or at plus.npr.org. Email us at considerthis@npr.org.This story was supported by the Pulitzer Center.This episode was produced by Matt Ozug, Karen Zamora and Elena Burnett, with audio engineering by Peter Ellena.It was edited by Patrick Jarenwattananon and William Troop.Our executive producer is Sami Yenigun.
Couple sues radiologist claiming he overlooked signs of both cancer and a spinal injury
Jeffrey Robinson first visited the emergency department at Central Maine Medical Center, Lewiston, in March 2023 complaining of back and stomach pain.
Analyst believes Alexandros Samodurov will commit to UNC
Greek center Alexandros Samodurov is heavily linked to UNC basketball. An analyst believes the Tar Heels are in a strong position.
TheBodyPro: Can gene therapy control HIV? Steven Deeks, M.D., explains the science
A single dose of anti-HIV duoCAR-T cellular therapy is safe — and might lead to sustained control of HIV in the absence of any ART in some individuals.
Forza Horizon 6 Has Its Own Boogeyman, and Players are Terrified
The myth of a Forza Horizon 6 Drivatar known as bowie knife99 is sending shivers down the spines of other players.
African countries can still get US funding for public health—if they cough up minerals and data first
New 'transactional' US global health agreements offer US aid for combatting HIV and other health threats in return for what critics say is expansive US access to resources.
Sunday Preview – Prepare to enter the Hive
See how you can get hold of the Special Edition of Dan Abnett’s new Warhammer 40,000 novel.
Intel's Latest Round Of Open-Source Projects Ended: OBS Studio Plugin, CVE Binary Tool & More
With Intel having been one of the most dominant open-source contributors for years across the software ecosystem, months after they began sunsetting various software projects no longer aligned with today's Intel, they continue formally sunsetting/archiving different open-source projects.
10 images of Iceland’s changing landscape
A new documentary uses archival photos to tell the story of the land of fire and ice.
From mall to main streets, Erie County businesses that are now gone
A selection from the GoErie.com archives captures Erie County businesses that have closed and the roles they once played in our communities.
The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
This fact sheet explores the history, funding, and future outlook of the President’s Emergency Plan for AIDS Relief (PEPFAR), the U.S. government's major global initiative to combat HIV/AIDS.
Global Health Watch: Ebola exposes gaps; WHA79 debates future of WHO; continued dismantling of US health leadership
The hantavirus outbreak and now emerging Ebola crisis are exposing major gaps in pandemic preparedness and global health cooperation; the future of the World Health Organization (WHO), multilateralism and the HIV response is being debated at this week’s World Health Assembly (WHA); while the US government continues to deconstruct its public health leadership. Emerging Ebola […]
Oxford Population Health: Global study of HIV variants underscores challenges for vaccine development
The largest-ever study mapping genetic variants of HIV-1 around the world shows the regional distribution of different subtypes of the virus continues to evolve.
KFF update: Assessing PEPFAR’s health spillover effects beyond HIV
KFF released two new analyses аssessing PEPFAR’s health, economic and educational spillover effects.
Philly health department notifies Center City dental patients of possible exposure to hepatitis, HIV
City health officials are recommending disease testing for some patients of Smiles at Rittenhouse Square following “unsanitary practices.”
Philly’s Smiles on the Square dental patients should get tested for HIV, hepatitis, health department says
The dentist's license has been temporarily suspended for unsafe sterilization practices.
Patients warned of possible exposure at dental clinic in Philadelphia's Rittenhouse
Patients at a dental clinic in Philadelphia's Rittenhouse section may have been exposed to hepatitis C, hepatitis B, and HIV, according to the Philadelphia Health Department
Assessing PEPFAR’s Health Spillover Effects Beyond HIV: An Update
This analysis updates prior work that assessed the association between PEPFAR investments and several health indicators, beyond HIV. It finds that PEPFAR continues to be associated with significant improvement in these broader health gains, suggesting a spillover effect beyond the program's HIV focus.
Dole Institute of Politics announces summer America at 250 programming
The Robert J. Dole Institute of Politics at the University of Kansas announced today its summer programming lineup in honor of the 250th anniversary of the signing of the U.S. Declaration of Independence on July 4. All events are free and open to the public.
Spirits brands look to sports, sponsorship and celebrity playbook to convert younger consumers
For advertisers like Chivas, Maker’s Mark and Jameson sports is the keystone of efforts to recruit younger drinkers and renew brand profiles.
Barcelona Institute for Global Health: Expanded TB screening does not speed up treatment initiation or improve survival in hospitalised patients with HIV
Adding molecular tests on sputum, urine and stool samples does not appear to outperform the standard WHO-recommended diagnostic approach.
Scientists Keep Finding Major Discoveries Lurking in Museum Backrooms
Here are six of the best.
Country music star left a ‘vast archive’ of unreleased music after his recent death
The beloved singer died in December.
🚨 Chivas - Cruz Azul line-ups confirmed
Chivas face Cruz Azul this afternoon in the second leg of the Clausura 2026 semifinal, a high-intensity clash after the 2-2 draw at Estadio Banorte. Los rojiblancos will play at home today at Estadio ...
Console Archives dev talks release plans and goals, wants to release over 800 games
Console Archives developer Hamster has spoken further about what’s planned going forward, including how many games we could ultimately see. Satoshi Hamada, the CEO and founder of Hamster Corporation, was talking about Console Archives in a recent Famitsu interview. He mentioned how during the planning stage, the company’s goal was “to reproduce every home console and every game ever”. Hamster...
📸 The week’s kit news 👕
Several major European clubs unveiled their new kits this week. OneFootball takes a full look at this week’s kit news.🔴⚪ Arsenal - Home 2026-27 (official)🔴 Manchester United - Home 2026-27 (...
Helio and You: Seasons on Earth, Mars, and Beyond
Earth has four seasons - spring, summer, fall, and winter. Other planets can experience seasons, too, but they might be wildly different from the ones that we are used to. Find out about how seasons work and what role the Sun plays in causing them.
Computer Science Grad Helps Develop AI System to Track Bee Pollen
On the edge of the Arboretum and Botanical Garden at Cal State Fullerton, honeybees return to their hive carrying tiny packets of pollen, a protein source that can mean the difference between a thriving colony and a collapse. But the warning signs are easy to miss. Class of 2026 computer science grad Kshitij Pingle is […]
Meet Chimba Sanga: Zambian physician, public health leader, LinkedIn influencer | Harvard T.H. Chan School of Public Health
Chimba Sanga, MPH ’26, is using his new training in epidemiology to improve HIV and TB care at home in Zambia.
Google Prepares "Googlebook" as a Chromebook Successor, Powered By Gemini
Google is preparing to refresh its laptop lineup, replacing the traditional Chromebook branding with the new "Googlebook" name. According to a now-deleted XDA Developers post, archived by some Redditors, Google is collaborating with several PC OEMs to launch what seems to be the successor to its wel...
Join the Keyhive at these Keyla Richardson American Idol watch parties
Pensacola's Keyla Richardson is in the 'American Idol' season finale. Check out these Pensacola area watch parties, where you can join in.
HIV i-Base: Transgender health in Australia: HIV drops by 94% as PrEP increases over 10 years
A ten year retrospective database study in Australia reported a 94% drop in HIV incidence among over 7,000 transgender and non-binary people.
Botswana’s former President Festus Mogae dies aged 86
The former leader won praise for good governance and the fight against HIV/AIDS in the southern African nation.
Bangor public health director reflects on HIV outbreak
Penobscot County has now logged 41 known cases of HIV, but there are likely more.
America’s oldest chartered hospital is now a Philly museum. Its lead curator wants you to have a ‘fabulous experience’
To mark Pennsylvania Hospital’s 275th anniversary, archivist Stacey Peeples is leading its transition into a museum for the public, open May 8.
Why a ‘Beehive’ school is again ranked as the Beehive State’s top high school
Several public charter schools crack the annual U.S. News & World Report’s Utah high school ‘top 10′ list
BioHive Week celebrates Utah's growing life science and healthcare industries
Utah’s life science and healthcare sectors are significant contributors to the Beehive State’s economy. The nonprofit BioHive plays an important role.
How Disneyland Remade American Politics
America is turning 250, and The Free Press is marking the occasion with a yearlong series of events, conversations, and stories celebrating our country’s history. Today, we’re taking a journey with historian Beverly Gage to Southern California. Beverly traded the archives for the open road for her new book, This Land is Your Land: A Road Trip Through U.S. History. We’re proud to publish an excerpt, on the theme park that shaped American politics—and the presidents who loved it. —The Editors On July 17, 1955, Ronald Reagan stood near a mocked-up wood-plank town in Anaheim, California, where a 13-star flag flew incongruously over an “Old West” landscape, and introduced the world to Disneyland. He had been invited by Walt Disney himself to co-host the park’s live ABC broadcast, alongside Art Linkletter and Bob Cummings—three Hollywood actors who seemed to embody a wholesome, all-American ethos. From the imagined past of Frontierland, the show leaped ahead to Tomorrowland, set in the far-off year of 1986, emphasizing the technical marvels yet to come: nuclear energy harnessed for civilian purposes, human beings riding rocket ships into space. Disney foretold great things for a 1980s in which the United States would serve as “a source of joy and inspiration to all the world.” But even he could not predict the most important political fact of the age: that his genial co-host would become president. Southern California was a strange place to build a park about the past, because the region at the time was all about newness and abundance and growth. For a lot of its history, Orange County had been Southern California’s version of flyover country: a vast agricultural expanse between two desirable places, Los Angeles and San Diego. But Disneyland was changing that. Before long, 50 miles south of deep-blue Hollywood, Orange County would become a region famed for its right-wing politics—but also for its mythmaking skills. Those two things, it turned out, went naturally together. ADVERTISEMENT The two presidents Southern California gave America both understood this instinctively. Richard Nixon and Reagan each built a national career on invoking a version of the American past in which the specificities of historical context mattered less than the big picture. For Nixon, progress meant proclaiming a “New American Revolution” on the eve of America’s bicentennial while dismantling the federal programs that had built the postwar middle class. For Reagan, it meant recapturing a lost optimism and an old-fashioned faith in America as an exceptional nation. Both men were less interested in history as it actually happened than in history as it felt—and Orange County, a place that had built itself almost entirely from scratch, turned out to be exactly where the myth of America’s future was getting made. I’m a historian—and historians tend to be myth-busters. With the country’s 250th birthday on the horizon, I figured it was a good time to step out of the ivory tower and check in with the past as it exists here and now, at the museums and monuments and roadside attractions where Americans go to learn about their history. After all my travels—to Davy Crockett’s Tennessee and Texas, to the real Erie Canal, to the birthplace of the American automobile and the actual Old West—I couldn’t miss out on Disneyland, the single most influential historic attraction in U.S. history.
Yerby Fellows present new research on mental health, stress, and HIV | Harvard T.H. Chan School of Public Health
The Yerby Fellowship Program provides a bridge between academic training in public health-related fields and entry-level faculty positions.
Amazon CEO Andy Jassy explains why Amazon is opening its supply chain to every business
In a recent interview, Jassy explained how Amazon built its logistics network for its own retail business—and why it's now offering those services to companies of all sizes.
Shivon Zilis clears the air around her relationship with Elon Musk
Elon Musk's lawsuit against OpenAI's Sam Altman features Shivon Zilis as a key witness. Zilis discusses her ties to Musk and denies leaking info.
Science: A novel gene-therapy approach to ‘functionally cure’ HIV succeeds in some monkeys
Six animals suppressed AIDS virus after one shot of treatment that makes cell-receptor antibody
Digital archive reveals how NIH built the field of genomics
Study details how taxpayer-funded agencies choose what science to support, previously a ‘black box’
Digital Archive Reveals How Research Agencies Fund Scientific Projects
A new digital archive developed by Northwestern scientists reveals how state-supported research funding agencies cooperate with the scientific community to decide to fund scientific research projects and support scientific innovation, as detailed in a recent study.
Global webinar – From evidence to essential services: embedding harm reduction in national health systems
Harm reduction services remain underfunded, fragmented, and often outside mainstream health systems, despite being an evidence-based, rights-based, and cost-effective approach, essential for achieving global HIV, hepatitis, and universal health coverage goals. This webinar will present WHO guidance and effective harm reduction approaches and respond to growing demand for practical dialogue on how to translate evidence into scalable national service models.
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Inter win Scudetto: How manager Cristian Chivu was able to restore winning mentality after UCL heartbreak
The Nerazzurri won their 21st Serie A title one year after losing 5-0 in the Champions League final
Marotta: ‘Inter showed courage choosing Chivu’
Inter President Beppe Marotta admits he didn’t expect Cristian Chivu to win the Scudetto in his first season, and potentially the Coppa Italia too. ‘We didn’t go in blind, but showed courage.’...